Precision medicine has moved from a scientific aspiration to a commercial and regulatory expectation in most major therapeutic areas. For pharma and biotech CEOs, that shift creates a governance challenge that is genuinely different in kind from traditional drug development oversight. Precision medicine programs do not live neatly inside R&D or commercial or regulatory functions. They span all three, and the organizational complexity that creates is one of the primary sources of value destruction in precision medicine investment.
The question is not whether to invest in precision medicine. For most companies with any oncology presence, and increasingly for those in immunology, neuroscience, and rare disease, the question is whether you are governing it with enough strategic clarity and CEO-level attention to capture the value you are building. Most are not.
What Makes Precision Medicine Governance Different
Traditional drug development governance follows a relatively linear path. Programs move through stages; each stage has defined decision points; the CEO’s involvement scales with capital at risk and strategic significance. Precision medicine disrupts that model in several ways that matter for how you allocate your time.
Companion diagnostics create a parallel development track. A drug with a companion diagnostic is not one program; it is two interdependent programs with different development timelines, different regulatory pathways, different commercial launch requirements, and often different external partners. The failure mode is not usually that either program fails on its own terms. It is that the coordination between them breaks down, and the drug arrives at approval without a commercial-ready diagnostic, or vice versa.
Biomarker strategy decisions compound early. The biomarker hypothesis you select in Phase 1 shapes everything downstream: trial design, patient population, regulatory labeling, commercial positioning, and reimbursement. Changing biomarker strategy in Phase 3 is enormously expensive if it is even possible. The CEO who is not engaged with biomarker strategy until late-stage development is ratifying a series of earlier decisions they never reviewed.
Data infrastructure is a strategic asset, not an IT decision. Precision medicine programs generate patient-level genomic, proteomic, and clinical data at a scale and specificity that creates long-term competitive value, but only if the infrastructure to capture, analyze, and deploy it is built with that intent. Data infrastructure decisions that look like capital expenditure line items are actually strategic capability bets. They need to be treated that way.
Patient stratification strategy has commercial and ethical dimensions. Deciding how narrowly to define your target patient population is not a purely scientific question. A tightly defined biomarker-selected population may have higher response rates and a cleaner regulatory path, but smaller commercial opportunity. A broader label may require a larger, more expensive trial and a more complex payer conversation. These trade-offs sit at the intersection of science, commercial strategy, and ethics in a way that cannot be resolved at the function level.
The CEO’s Role in Companion Diagnostic Strategy
Companion diagnostic decisions are among the highest-leverage precision medicine choices a CEO can influence, and among the most commonly under-governed at the CEO level.
Build, Partner, or License
The first strategic decision is whether to develop your companion diagnostic internally, partner with a diagnostics company, or license an existing platform. Each path carries different implications for timeline, cost, control, and long-term competitive positioning. Diagnostics companies like Roche, Foundation Medicine, or Illumina bring regulatory expertise and commercial infrastructure, but the partnership agreement will shape your label, your commercial positioning, and your data rights for years.
This decision should not be delegated to your business development team or your CSO alone. The CEO needs to be the integrating voice across the commercial, regulatory, and scientific dimensions of the choice. A 90-minute working session with your relevant functional leaders when a major companion diagnostic partnership decision is pending is not excessive; it is the minimum.
Regulatory Co-development
Companion diagnostics require FDA approval on a coordinated timeline with the drug. The regulatory strategy oversight implications of this are significant. When a drug-diagnostic combination faces questions about analytical validity, clinical validity, or the appropriate biomarker threshold for patient selection, the CEO needs to be engaged, not because you will resolve the scientific questions, but because the regulatory trade-offs often have commercial and strategic dimensions that require executive authority to navigate.
CEOs who treat companion diagnostic regulatory strategy as a purely technical matter tend to find themselves surprised by labeling decisions that limit commercial opportunity in ways that could have been anticipated and negotiated differently.
Commercial Readiness Alignment
The diagnostic needs to be commercially available when the drug is approved. That sounds obvious, but the organizational gap between drug development timelines and diagnostic commercial readiness is one of the most common precision medicine execution failures. Your commercial team needs to be planning diagnostic launch infrastructure at the same time your clinical team is conducting the pivotal trial. Ensuring that alignment exists is a CEO-level accountability, because it requires coordinating across functions that do not naturally communicate with each other on this timeline.
Biomarker Program Oversight
Biomarker strategy is where many precision medicine programs either create durable competitive advantage or accumulate hidden strategic risk. McKinsey research on precision medicine has consistently found that biomarker program failures are more often strategic and organizational than scientific. The biology is usually tractable; the governance is not.
Establishing the Biomarker Governance Model
Your biomarker programs need a governance structure that is clearly owned. In most pharma organizations, biomarker work lives somewhere between translational medicine, clinical pharmacology, and clinical development, with partial accountability in each and full accountability in none. The CEO’s role is to ensure that biomarker strategy has a clear owner at the senior level and that the owner has sufficient authority to make decisions across functional boundaries.
A biomarker steering committee that reports to the CSO or Chief Medical Officer, with a mandate that includes both scientific and strategic dimensions of biomarker selection, is a common solution. What matters is not the structure but the clarity of accountability and the quality of the escalation path when biomarker decisions have strategic implications.
Patient Stratification Decisions That Require CEO Input
Not every biomarker decision needs to reach the CEO. The ones that do are those where the choice between broader and narrower patient selection creates a material strategic trade-off. If you are deciding whether to pursue an all-comers label versus a biomarker-selected label in a major indication, that is a decision with implications for trial design, capital allocation, commercial ceiling, payer strategy, and competitive positioning. It belongs at your level.
The framing you want from your team when these decisions come to you is not a scientific recommendation with a request for approval. It is a structured trade-off analysis: here are the three patient stratification options, here are the regulatory, commercial, and scientific implications of each, and here is our recommendation and the reasoning. Your role is to stress-test the strategic logic, ensure that commercial and regulatory perspectives have been genuinely integrated, and make the call when the trade-offs are sufficiently material.
Data Infrastructure as a Strategic Priority
The patient-level data generated by precision medicine programs is one of the most valuable long-term assets a pharmaceutical company can build, and it is one of the most consistently under-invested. The reason is structural: data infrastructure investments are capital expenditures that show up immediately on the P&L, while the strategic value they create materializes over years and is difficult to attribute.
CEOs who do not actively govern data infrastructure investment tend to find that precision medicine programs generate enormous scientific value that the organization cannot fully capture because the infrastructure to reuse, analyze, and build on that data was never built.
What You Should Be Asking
The right CEO questions on precision medicine data infrastructure are not technical. They are strategic. Are we building data assets that will compound in value over time, or are we generating data that we cannot reuse across programs? Do we own our patient data in a form that supports future development, or have we structured our partnerships in ways that limit our data rights? Is our data infrastructure capable of supporting the AI and machine learning applications that will shape drug discovery and development in the next decade?
These questions require input from your Chief Data Officer or equivalent, your research leadership, and your legal team. They also require CEO ownership, because the cross-functional nature of the investment and the time horizon of the value creation put the trade-offs outside the authority of any single function.
Partnerships and Data Rights
Many precision medicine programs involve external partners, whether diagnostics companies, genomics platforms, academic medical centers, or technology companies. Each of those partnerships creates data rights questions that have long-term strategic implications. A CEO who is not paying attention to data rights provisions in precision medicine partnerships is ceding strategic value that cannot be recovered after the agreement is signed.
Organizational Complexity: The Cross-Functional Governance Problem
The most distinctive challenge in precision medicine program governance is organizational. Precision medicine programs span research, translational medicine, clinical development, regulatory affairs, medical affairs, market access, and commercial, at the same time, not sequentially. The organizational model that works for traditional drug development, with handoffs between functions at defined stage gates, does not work for precision medicine.
Building a Cross-Functional Operating Model
The CEO’s role here is to establish and protect a cross-functional operating model for precision medicine programs that gives them organizational coherence. That typically means a program-level structure with a single accountable leader who has authority to coordinate across functions, not just convene them.
The accountability question is critical. Precision medicine programs that are governed by committee, where R&D, commercial, and regulatory each have partial ownership, tend to make slow decisions and miss coordination points. The CEO needs to be explicit about who is accountable for the end-to-end precision medicine program and ensure that the organizational model supports that accountability with the right resources and authority.
Time Allocation Across the Precision Medicine Lifecycle
Your time investment in precision medicine governance should be front-loaded relative to when capital is at risk. The decisions that determine value creation or destruction in precision medicine programs are made early, in biomarker selection, trial design, diagnostic partnership structure, and data infrastructure investment. By the time a precision medicine program reaches late-stage development, the strategic architecture is largely set.
A practical allocation: precision medicine strategy should be a standing agenda item in your quarterly R&D leadership reviews. Major biomarker strategy decisions, companion diagnostic partnership choices, and data infrastructure investments above a defined threshold should come to you directly. You should have a semi-annual review of your precision medicine portfolio that looks at the cross-program view: where are we concentrated? Where are we building durable data assets? Where is our biomarker strategy creating competitive differentiation, and where are we following rather than leading?
For CEOs governing a portfolio that includes programs at multiple development stages, the link between precision medicine governance and broader pipeline review process is direct. Precision medicine programs often look more complex than they are in stage-gate reviews because the companion diagnostic track and the biomarker data streams are not well represented in standard pipeline reporting formats. Ensuring your pipeline review process captures precision medicine-specific milestones and risks is a governance hygiene issue worth addressing directly.
The Reimbursement Dimension
Precision medicine programs face a reimbursement environment that is structurally different from traditional drugs, and CEOs who do not engage with this early in program development tend to face painful surprises at launch. Payers are increasingly sophisticated about biomarker-defined populations, and the value narrative for a precision medicine product must be built around the patient stratification logic from the beginning.
The question of which patients respond and why is not just a scientific question for FDA; it is the central commercial and reimbursement narrative. Health technology assessment bodies in Europe, and increasingly the US managed care organizations, want to understand not only that the drug works in the selected population, but why the biomarker selection is clinically and economically justified.
CEOs who are engaged with biomarker strategy early are in a much better position to ensure that the trial design captures the evidence that payers will need. This is a case where CEO-level integration of scientific, regulatory, and commercial thinking at program inception creates value that cannot be recovered by any amount of post-hoc value demonstration activity at launch.
Building Precision Medicine as an Organizational Capability
The final dimension of CEO time investment in precision medicine is organizational capability building. Precision medicine requires capabilities in translational science, biomarker development, diagnostics partnership management, data science, and patient stratification analytics that most traditional pharma organizations do not have at scale. Building those capabilities requires deliberate investment decisions, talent strategy choices, and in some cases, acquisitions or significant partnerships.
The CEO’s role is to make explicit the organizational capability bets the company is making in precision medicine, and to ensure those bets are coherent with the therapeutic area strategy and pipeline composition. A company pursuing a precision medicine strategy in oncology without building internal biomarker development capability is creating a structural dependency that will constrain its strategic options over time.
Precision medicine is not a feature that can be added to a drug development program at the last minute. It is a strategic orientation that shapes how you discover targets, design trials, build partnerships, invest in data infrastructure, and engage with regulators and payers. Governing it well is one of the defining CEO challenges in contemporary pharmaceutical leadership.